Company: CNTB
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001835268-25-000014
Chunk: 275

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 275
---
 the year ended December 31, 2024 and 2023 was $128,000 and $2,000, respectively. As of December 31, 2024 and 2023, the total intrinsic value of options outstanding and exercisable was $0.5 million and $0.2 million, respectively.Years Ended December 31,20242023OptionsWeighted-AverageExercise PriceOptionsWeighted-AverageExercise PriceExercisable at end of year4,252,615$6.29 2,998,933$6.94 Options vested or expected to vest14,263,242 $2.93 6,514,909$5.10 

127

Exercise prices and weighted-average remaining contractual lives for the options outstanding as of December 31, 2024 were:OutstandingOptionsRange ofExercisesPricesWeighted-AverageRemainingContractualLife (in years)Weighted-AverageExercise PriceOptionsExercisableWeighted-AverageExercise Priceof OptionsExercisable3,245,976$0.75 - $1.138.94$0.93 657,080$0.82 3,489,825$1.15 - $1.738.22$1.22 709,996$1.26 4,532,973$1.77 - $2.669.38$1.77 73,749$1.97 732,504$3.05 - $4.582.60$4.17 697,625$4.17 589,829$4.70 - $7.055.46$4.70 469,911$4.70 1,344,385$8.16 - $12.241.78$10.05 1,341,089$10.05 327,750$16.41 - $24.624.50$21.75 303,165$21.70 14,263,242$0.75 - $24.627.66$2.93 4,252,615$6.29 On December 31, 2024, we had reserved 14,263,242 ordinary shares for future issuance on exercise of outstanding options granted under the 2019, 2021 and Inducement Plans.Share-Based CompensationThe following summarizes share-based compensation expense related to share-based payment awards pursuant to our equity compensation arrangements (in thousands):December